Table 1.
Clinical characteristics
| Patients studied (n = 44) | |
|---|---|
| Age (years) | 64.8 ± 11.6 (26–82) |
| Male sex | 42 (95.5%) |
| Hypertension | 28 (63.6%) |
| Diabetes | 20 (46.5%) |
| Dyslipidaemia | 27 (62.8%) |
| COPD | 6 (15.0%) |
| CKD | 11 (28.9%) |
| NYHA class | |
| I | 7 (20.6%) |
| II | 23 (67.6%) |
| III and IV | 4 (11.8%) |
| Ischaemic cardiomyopathy | 31 (70.5%) |
| Permanent AF | 10 (23.3) |
| ACEIs | 23 (60.5%) |
| Beta-blockers therapy | 29 (76.3%) |
| Sotalol therapy | 4 (10.5%) |
| Amiodarone therapy | 31 (81.6%) |
| VT storm | 7 (15.9%) |
| LVEF (%) | 32.3 ± 7.8 |
| LVEDD (mm) | 61.4 ± 10.2 |
AF, atrial fibrillation; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ACEIs, angiotensin-converting enzyme inhibitors; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; NYHA, New York Heart Association; VT, ventricular tachycardia.